{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:57:17Z","timestamp":1777111037158,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Due to the embryotoxicity found in animal studies and scarce clinical data in pregnant women, it is still controversial whether entecavir (ETV) and adefovir dipivoxil (ADV) are safe during human pregnancy. This is of paramount importance when counseling pregnant women with hepatitis B virus (HBV) on risks and benefits to their offspring.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To quantify the association between administration of ETV and ADV in pregnant women and occurrence of adverse events (AEs) during pregnancy (AEDP).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Pregnancy reports from the FDA Adverse Event Reporting System (FAERS) were used to perform a retrospective analysis of AEDP associated with ETV or ADV. Disproportionality analysis estimating the reporting odds ratio (ROR) was conducted to identify the risk signals. A signal was defined as ROR value &amp;gt;2, and lower limit of 95% confidence interval (CI)&amp;gt; 1.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 1,286,367 reports involving AEDP were submitted to FAERS by healthcare professionals. Of these, there were 547 cases reporting ETV and 242 cases reporting ADV as primary suspected drugs. We found a moderate or strong signal for increased risk of spontaneous abortion when comparing ETV with tenofovir disoproxil fumarate (TDF) and telbivudine (LdT), with RORs equal to 1.58 (95% CI, 1.09\u20132.30) and 2.13 (95% CI, 1.04\u20134.36), respectively. However, when the included reports were limited to indication containing HBV infection, no signals for increased AEDP were detected. Futhermore, a strong signal for increased risk of spontaneous abortion was identified in patients with HBV infection when comparing ETV or ADV with lamivudine (LAM), with RORs of 3.55 (95% CI, 1.54\u20138.18) and 2.85 (95% CI, 1.15\u20137.08), respectively.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We found a strong signal for increased risk of spontaneous abortion in patients with HBV infection taking ETV or ADV, in comparison with those prescribed with LAM. Moreover, no obvious signal association of human teratogenicity with exposure to ETV or ADV was identified in fetuses during pregnancy. Nevertheless, owing to the limitations of a spontaneous reporting database, which inevitably contains potential biases, there is a pressing need for well-designed comparative safety studies to validate these results in clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2021.772768","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T07:26:26Z","timestamp":1641194786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System"],"prefix":"10.3389","volume":"12","author":[{"given":"Renjun","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuoya","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Faiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/pds.5105","article-title":"Safety Concerns Reported by Consumers, Manufacturers and Healthcare Professionals: A Detailed Evaluation of Opioid-Related Adverse Drug Reactions in the FDA Database over 15 Years","volume":"29","author":"Andreaggi","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B2","unstructured":"Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 20212021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral Therapy in Chronic Hepatitis B Viral Infection during Pregnancy: A Systematic Review and Meta-Analysis","volume":"63","author":"Brown","year":"2016","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1177\/1352458520949986","article-title":"Adverse Event Profile Differences between Rituximab and Ocrelizumab: Findings from the FDA Adverse Event Reporting Database","volume":"27","author":"Caldito","year":"2021","journal-title":"Mult. Scler."},{"key":"B5","doi-asserted-by":"publisher","first-page":"612259","DOI":"10.3389\/fphar.2020.612259","article-title":"Inflammasome Targeted Therapy in Pregnancy: New Insights from an Analysis of Real-World Data from the FAERS Database and a Systematic Review","volume":"11","author":"Carnovale","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"616505","DOI":"10.3389\/fphar.2021.616505","article-title":"Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study from 2014 to 2019 Based on FAERS","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of Data Mining at the Food and Drug Administration","volume":"23","author":"Duggirala","year":"2016","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"621691","DOI":"10.3389\/fphar.2021.621691","article-title":"Head-to-head Comparison of Sedation and Somnolence Among 37 Antipsychotics in Schizophrenia, Bipolar Disorder, Major Depression, Autism Spectrum Disorders, Delirium, and Repurposed in COVID-19, Infectious Diseases, and Oncology from the FAERS, 2004-2020","volume":"12","author":"Eugene","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and Safety of Antiviral Prophylaxis during Pregnancy to Prevent Mother-To-Child Transmission of Hepatitis B Virus: a Systematic Review and Meta-Analysis","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14767058.2020.1723540","article-title":"Pregnancy Outcomes for Pregnant Women with Chronic Hepatitis B Exposing to Entecavir or Adefovir Dipivoxil Therapy before or in Early Pregnancy","volume":"4","author":"Gao","year":"2020","journal-title":"J. Matern. Fetal Neonatal. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3851\/IMP1813","article-title":"Antiviral Therapy for Hepatitis B Infection during Pregnancy and Breastfeeding","volume":"16","author":"Giles","year":"2011","journal-title":"Antivir. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s11096-021-01273-8","article-title":"Evaluation of Rivaroxaban-, Apixaban- and Dabigatran-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System (FAERS) Database","volume":"43","author":"Guo","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00003495-199958010-00015","article-title":"Lamivudine. A Review of its Therapeutic Potential in Chronic Hepatitis B","volume":"58","author":"Jarvis","year":"1999","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/ccr3.3896","article-title":"Entecavir Administration to Pregnant Japanese Woman with Chronic Hepatitis B and Hepatocellular Carcinoma: A Case Report","volume":"9","author":"Kakiuchi","year":"2021","journal-title":"Clin. Case Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00404-011-2064-x","article-title":"Chronic Hepatitis B Infection in Pregnancy Illustrated by a Case of Successful Treatment with Entecavir","volume":"284","author":"Kakogawa","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2165\/00003495-200767130-00011","article-title":"Telbivudine","volume":"67","author":"Keam","year":"2007","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"663088","DOI":"10.3389\/fphar.2021.663088","article-title":"Pericardial Toxicities Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular Carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00126334-200108150-00005","article-title":"Adefovir and Tenofovir Susceptibilities of HIV-1 after 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS-96-408","volume":"27","author":"Miller","year":"2001","journal-title":"J. Acquir Immune Defic Syndr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2165\/10482940-000000000-00000","article-title":"Tenofovir Disoproxil Fumarate: in Chronic Hepatitis B","volume":"69","author":"Perry","year":"2009","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.placenta.2018.07.005","article-title":"Regulation of Human Placental Drug Transporters in HCV Infection and Their Influence on Direct Acting Antiviral Medications","volume":"69","author":"Pfeifer","year":"2018","journal-title":"Placenta"},{"key":"B22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The Reporting Odds Ratio and its Advantages over the Proportional Reporting Ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data Mining of the Public Version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14218\/JCTH.2019.00021","article-title":"Comparing the Efficacy and Safety of Treating Chronic Hepatitis B Infection during Pregnancy with Lamivudine, Telbivudine, and Tenofovir: A Meta-Analysis","volume":"7","author":"Sali","year":"2019","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/QAD.0b013e3282ffde91","article-title":"The Anti-HIV Activity of Entecavir: a Multicentre Evaluation of Lamivudine-Experienced and Lamivudine-Naive Patients","volume":"22","author":"Sasadeusz","year":"2008","journal-title":"AIDS"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2165\/00003495-200969080-00005","article-title":"Entecavir: a Review of its Use in Chronic Hepatitis B","volume":"69","author":"Scott","year":"2009","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S437","DOI":"10.1093\/cid\/ciu709","article-title":"Designing Drug Trials: Considerations for Pregnant Women","volume":"59","author":"Sheffield","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41575-020-00361-w","article-title":"Viral Hepatitis and Pregnancy","volume":"18","author":"Terrault","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamadermatol.2019.1388","article-title":"US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated with Isotretinoin","volume":"155","author":"Tkachenko","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/1753193418805249","article-title":"The Teratogenic Effects of Thalidomide on Limbs","volume":"44","author":"Vargesson","year":"2019","journal-title":"J. Hand Surg. Eur. Vol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a Major Update to the DrugBank Database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12072-020-10026-0","article-title":"Efficacy and Safety of Antiviral Therapy for HBV in Different Trimesters of Pregnancy: Systematic Review and Network Meta-Analysis","volume":"14","author":"Wu","year":"2020","journal-title":"Hepatol. Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/10543406.2020.1783284","article-title":"Evaluating Medical Device Adverse Event Signals Using a Likelihood Ratio Test Method","volume":"31","author":"Xu","year":"2021","journal-title":"J. Biopharm. Stat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijgo.2011.03.004","article-title":"Efficacy of Peripartum Antiviral Treatment for Hepatic Failure Due to Hepatitis B Virus","volume":"114","author":"Yu","year":"2011","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B Virus Infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.772768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T07:26:29Z","timestamp":1641194789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.772768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":36,"alternative-id":["10.3389\/fphar.2021.772768"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.772768","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"article-number":"772768"}}